Abstract
Variably protease-sensitive prionopathy (VPSPr) is a rare, atypical subtype of prion disease currently classified as sporadic. We performed exome sequencing and targeted sequencing of PRNP non-coding regions on genomic DNA from autopsy-confirmed VPSPr patients (N=67) in order to search for a possible genetic cause. Our search identified no potentially causal variants for VPSPr. The common polymorphism PRNP M129V was the largest genetic risk factor for VPSPr, with an odds ratio of 7.0. Other variants in and near PRNP exhibited association to VPSPr risk only in proportion to their linkage disequilibrium with M129V, and upstream expression quantitative trait loci showed no evidence of independent association to VPSPr risk. We cannot rule out the possibility of causal variants hiding in genomic regions or classes of genetic variation that our search did not canvas. Nevertheless, our data support the classification of VPSPr as a sporadic prion disease.
Author Summary Prion disease is caused by misfolding of the prion protein (PrP), and can be either sporadic genetic, or acquired. Acquired cases arising from infection through dietary or medical routes are exceedingly rare today (<1% of cases). Sporadic cases occur apparently at random, without any major genetic risk factors, and are not passed down to subsequent generations. All cases of genetic prion disease to date have been traced to DNA changes that alter the amino acid sequence of PrP, and children of people with genetic prion disease are at 50/50 risk of inheriting these autosomal dominant DNA changes. Variably protease sensitive prionopathy, or VPSPr, is a rare and unusual subtype of prion disease, classified as sporadic because there are no changes in PrP’s amino acid sequence. Here we performed DNA sequencing on 67 VPSPr cases to determine whether a genetic variant outside of the PrP amino acid sequence might cause the disease. We found no DNA changes that could potentially cause VPSPr. While it is difficult to prove the negative — a causal genetic change could still exist in some part of the genome where we did not search — our data support the notion that VPSPr is truly sporadic in nature, and that risk of VPSPr is not transmitted in families.
Competing Interest Statement
EVM acknowledges speaking fees from Abbvie, Eli Lilly, and Vertex; consulting fees from Alnylam and Deerfield; research support from Eli Lilly, Gate Bio, Ionis, and Sangamo. SMV acknowledges speaking fees from Abbvie, Biogen, Eli Lilly, Illumina, and Ultragenyx; consulting fees from Alnylam and Invitae; research support from Eli Lilly, Gate Bio, Ionis, and Sangamo. BSA acknowledges research funding from CDC, NIH, CJD Foundation, and Ionis and consulting fees from Ionis, Sangamo, and Gate Bio, and royalties from Wolter Klower. AODL acknowledges consulting fees from Tome Biosciences, Ono Pharma USA, Addition Therapeutics, and Congenica; and research funding from Pacific Biosciences.
Funding Statement
This study was funded by the National Institutes of Health (R03 NS123786). Broad CMG control cohort sequencing was funded by NIH grants UM1 HG008900 and U01 HG011755, and seqr analysis platform by R01 HG009141.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Broad Institute Office of Research Subjects Protection (NHSR-5256)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Response to reviewers round 1
Data Availability
All figures and statistics in this manuscript were generated using custom scripts in R 4.4.1. Genomic and phenotypic data for the Broad CMG cohort used for comparison is available via dbGaP accession numbers phs003047 and phs001272. Access is managed by a data access committee designated by dbGaP and is based on intended use of the requester and allowed use of the data submitter as defined by consent codes. Raw data and source code sufficient to reproduce the figures and statistics in this manuscript will be made available at https://github.com/ericminikel/vpspr
